Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
AssigneeThe University of North Carolina at Chapel Hill
InventorsMonroe J. Stutts, III, Richard C. Boucher, Jr., Eduardo R. Lazarowski, Cara A. Geary
Life of this patent
Estimating the term…
Abstract
A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is disclosed: ##STR1## wherein: n is from 1 to 6; X is --OH or --SH; A and B are each independently selected from the group consisting of: ##STR2## wherein R is H or Br. The compounds are useful in the treatment of airway diseases such as cystic fibrosis. Pharmaceutical formulations comprising a compound of Formula (I), and methods of hydrating mucous secretions in the lungs of a subject in need of such treatment, comprising administering to the lungs of the subject a compound of Formula I as given above, are also disclosed.
Claims8
A method of hydrating mucous secretions in the lungs of a subject in need of such treatment, comprising administering to the lungs of the subject a compound of Formula I below, or a pharmaceutically acceptable salt thereof, in an amount effective to hydrate lung mucous secretions:
- ##STR5## wherein:
- n is from 1 to 6;
- X is --OH or --SH;
- and
- A and B are each independently selected from the group consisting of:
- ##STR6## wherein R is H or Br;
- and wherein said compound of Formula I comprises an aerosol of respirable particles having a particle size within the range of about 1 to 5 microns.
A method of treating cystic fibrosis in a human subject in need of such treatment, comprising administering by inhalation an aerosol suspension of respirable particles to the respiratory system of said subject, said particles comprised of a compound of Formula I below, or a pharmaceutically acceptable salt thereof:
- ##STR7## wherein:
- n is from 1 to 6;
- X is --OH or --SH;
- and
- A and B are each independently selected from the group consisting of:
- ##STR8## wherein R is H or Br;
- in an amount effective to hydrate retained lung mucous secretions in the lungs of said subject, wherein said compound of Formula I comprises an aerosol of respirable particles having a particle size within the range of about 1 to 5 microns, and whereby the retained mucous secretions are more easily transported from the lungs via mucociliary action.
Dependencies are inferred from the claim text.